S. Kopetz

Robyn L. Temple-Smolkin, D. Sargent, Christina B. Ventura, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Robyn L. Temple-Smolkin, D. Sargent, Christina B. Ventura, 2017, The Journal of molecular diagnostics : JMD.

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer

Jeffrey S. Morris, S. Hamilton, S. Kopetz, 2016, British Journal of Cancer.

Biomarker-guided therapy for colorectal cancer: strength in complexity

R. Lothe, S. Kopetz, A. Sveen, 2019, Nature Reviews Clinical Oncology.

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.

Funda Meric-Bernstam, Gordon B Mills, Michael A Davies, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications

K. Hess, J. Ajani, F. Meric-Bernstam, 2019, JCO precision oncology.

Platelets: “First Responders” in Cancer Progression and Metastasis

E. Hawk, A. Sood, S. Kopetz, 2017 .

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

M. Ychou, S. Kopetz, R. Wolff, 2017, Clinical Cancer Research.

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

P. Elvin, S. Kopetz, M. Overman, 2014, BMC Cancer.

Multicenter validation study of pathologic response and tumor thickness at the tumor‐normal liver interface as independent predictors of disease‐free survival after preoperative chemotherapy and surgery for colorectal liver metastases

J. Vauthey, B. Nordlinger, T. Gruenberger, 2013, Cancer.

Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?

W. Wu, P. Scheet, S. Kopetz, 2017, Clinical Cancer Research.

Differing total mRNA expression shapes the molecular and clinical phenotype of cancer

P. A. Futreal, P. Campbell, P. Boutros, 2020, bioRxiv.

Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer

Jeffrey S. Morris, Kyle Chang, K. Tomczak, 2020, Gut.

Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract

A. Maitra, J. Shen, S. Kopetz, 2020, bioRxiv.

Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity.

J. Skibber, S. Kopetz, M. Overman, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Gene-Specific Methylation Profiles for Integrative Methylation-Expression Analysis in Cancer Research

Jeffrey S. Morris, K. Baggerly, B. Broom, 2019, bioRxiv.

Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.

F. Meric-Bernstam, I. Shureiqi, S. Kopetz, 2014 .

Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.

S. Friend, M. Delorenzi, J. Guinney, 2014 .

The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.

S. Kopetz, S. Raghavan, A. Dasari, 2022, Clinical colorectal cancer.

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.

L. Ellis, S. Curley, E. Abdalla, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

J. Desai, H. Lenz, S. Kopetz, 2016 .

Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors

Qing Yang, S. Kopetz, Shulin Li, 2022, Journal for ImmunoTherapy of Cancer.

Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target

K. Aldape, K. Nathanson, Ju-Seog Lee, 2014, Clinical Cancer Research.

Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer.

S. Kopetz, R. Wolff, M. Overman, 2021, Journal of gastrointestinal oncology.

Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.

S. Kopetz, R. Wolff, M. Overman, 2014, Clinical colorectal cancer.

Patient-derived micro-organospheres enable clinical precision oncology.

Anders B. Dohlman, J. Shen, H. Clevers, 2022, Cell stem cell.

Tumor cell total mRNA expression shapes the molecular and clinical phenotype of cancer

M. Nykter, T. Speed, P. Campbell, 2021 .

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

S. Reddy, I. Shureiqi, S. Kopetz, 2015, Investigational New Drugs.

FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.

I. Shureiqi, S. Kopetz, R. Wolff, 2020, Clinical colorectal cancer.

Novel Therapies in Development for Metastatic Colorectal Cancer.

S. Kopetz, Michael S. Lee, 2014, Gastrointestinal cancer research : GCR.

Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer.

E. Holliday, C. Taniguchi, A. Koong, 2021, Clinical colorectal cancer.

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis

S. Kopetz, A. Parikh, M. Jen, 2022, The oncologist.

Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.

J. Vauthey, S. Kopetz, M. Overman, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Systemic Therapy for Non-operable Colorectal Cancer Metastases

S. Kopetz, P. Hoff, 2009 .

Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.

J. Marshall, S. Kopetz, A. Pereira, 2019, The oncologist.

Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.

J. Vauthey, C. Charnsangavej, S. Kopetz, 2009, Clinical colorectal cancer.

Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016

L. Ellis, S. Kopetz, M. Overman, 2022, JAMA network open.

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.

Myung Ah Lee, J. Krauss, V. Heinemann, 2021, The Lancet. Oncology.

Integrated safety summary for trifluridine/tipiracil (TAS-102)

E. Van Cutsem, S. Kopetz, J. Bendell, 2018, Anti-cancer drugs.

Efficacy of Sym 004 in PatientsWithMetastatic Colorectal CancerWith Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNAAnalyses A Phase 2 Randomized Clinical Trial

C. Nadal, R. Salazar, A. Bardelli, 2018 .

Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors

M. Fukushima, S. Kopetz, R. Wolff, 2008, Cancer investigation.

Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy

J. Vauthey, S. Kopetz, C. Conrad, 2014, Journal of surgical oncology.

Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases

J. Vauthey, S. Kopetz, C. Conrad, 2018, The British journal of surgery.

High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.

S. Curley, E. Abdalla, J. Vauthey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Commentary: practice patterns and potential impact on quality measures for a practicing physician.

S. Kopetz, C. Eng, 2009, Journal of oncology practice.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia

J. Vauthey, B. Hobbs, L. Saltz, 2018, Journal of the National Cancer Institute.

Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab

J. Vauthey, M. Ychou, Haesun Choi, 2017, Gut.

Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases

J. Vauthey, S. Kopetz, C. Conrad, 2017, Annals of Surgical Oncology.

Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy

J. Skibber, S. Kopetz, R. Wolff, 2017, American journal of clinical oncology.

Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis

J. Skibber, S. Kopetz, D. Weksberg, 2017, Advances in radiation oncology.

Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course.

P. Bhosale, J. Skibber, S. Kopetz, 2009, International journal of radiation oncology, biology, physics.

Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival

S. Curley, E. Abdalla, J. Vauthey, 2007, Journal of Gastrointestinal Surgery.

Reply to S. Boutayeb et al.

A. Khorana, L. Saltz, S. Kopetz, 2020, JCO oncology practice.

Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Bradford J. Kim, J. Vauthey, S. Kopetz, 2017, Annals of Surgical Oncology.

Hurdles and complexities of codon 13 KRAS mutations.

S. Kopetz, M. Morelli, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hurdles and Complexities of Codon 13

S. Kopetz, M. Morelli, 2012 .

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

R. Labianca, R. Schilsky, J. Berlin, 2018, European journal of cancer.

Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting

Jeffrey S. Morris, I. Wistuba, B. Broom, 2020, Clinical Cancer Research.

Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery.

J. Vauthey, S. Kopetz, D. Maru, 2022, Journal of the American College of Surgeons.

Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression

P. A. Futreal, M. Nykter, T. Speed, 2022, Nature Biotechnology.

Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer.

Steven J. M. Jones, Ryan D. Morin, M. Marra, 2020, Clinical colorectal cancer.

Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

S. Kopetz, M. Overman, Amir Mehrvarz Sarshekeh, 2018, Future oncology.

Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology.

S. Kopetz, A. Katsiampoura, 2014, Gastrointestinal cancer research : GCR.

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.

P. Angenendt, S. Kopetz, F. Janku, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary

J. Vauthey, S. Kopetz, T. Aloia, 2012, British Journal of Cancer.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Robyn L. Temple-Smolkin, D. Sargent, Christina B. Ventura, 2017, Journal of oncology practice.

APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases

J. Vauthey, S. Kopetz, C. Conrad, 2017, Annals of surgery.

Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules.

J. Vauthey, S. Kopetz, Y. Mise, 2016, Annals of surgery.

Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?

J. Vauthey, S. Kopetz, R. Mehran, 2015, Annals of Surgical Oncology.

A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries

Jing Wang, J. Ajani, Steven H. Lin, 2019, Disease Models & Mechanisms.

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

C. Takimoto, S. Kopetz, A. Mita, 2019, Investigational New Drugs.

Precision combination therapies based on recurrent oncogenic co-alterations

C. Sander, A. Luna, Anil Korkut, 2020, bioRxiv.

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer

Gerald C. Chu, R. DePinho, Kyle Chang, 2017, Genes & development.

The somatic mutation landscape of premalignant colorectal adenoma

J. Gu, Xifeng Wu, Y. Ye, 2017, Gut.

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

G. Mills, F. Meric-Bernstam, S. Hamilton, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients.

A. Rashid, S. Kopetz, James C Yao, 2015, Clinical colorectal cancer.

Coordination of care in colon cancer

S. Kopetz, G. Chang, 2015, Cancer.

AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation

J. Yun, W. Jia, S. Kopetz, 2019, Oncogene.

New therapies and insights into the changing landscape of colorectal cancer

S. Kopetz, 2018, Nature Reviews Gastroenterology & Hepatology.

Bioactive lipid metabolism in platelet “first responder” and cancer biology

E. Hawk, A. Sood, S. Kopetz, 2018, Cancer and Metastasis Reviews.

Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development

E. Hawk, Manu Sebastian, S. Kopetz, 2020, BMC cancer.

Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic.

S. Kopetz, 2007, Gastrointestinal cancer research : GCR.

Colon Cancer in Patients Under 25 Years Old: A Different Disease?

S. Kopetz, A. Hayes-Jordan, G. Sandler, 2020, Journal of the American College of Surgeons.

Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?

S. Kopetz, V. Morris, A. Dasari, 2019, JAMA oncology.

Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.

S. Hamilton, I. Shureiqi, S. Kopetz, 2014 .

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

P. Gibbs, J. Desai, R. Broaddus, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

OP-JNCI200054 208..211

S. Kopetz, M. Overman, V. Morris, 2021 .

Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer.

S. Kopetz, M. Overman, V. Morris, 2020, Journal of the National Cancer Institute.

Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases

S. Curley, E. Abdalla, J. Vauthey, 2010, Annals of Surgical Oncology.

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

E. Van Cutsem, J. Tabernero, R. Yaeger, 2022, ESMO open.

Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy

M. Wallace, S. Kopetz, R. Wolff, 2008, Cancer.

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

L. Ellis, S. Kopetz, J. Abbruzzese, 2009, Cancer research.

Circulating tumor DNA as a marker of minimal residual disease in colorectal cancer.

S. Kopetz, 2020, Clinical advances in hematology & oncology : H&O.

Is the Patient Cured?

H. Burke, S. Kopetz, 2019, JAMA oncology.

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma

J. Ajani, Steven H. Lin, S. Kopetz, 2019, Therapeutic advances in medical oncology.

An R Implementation of Tumor-Stroma-Immune Transcriptome Deconvolution Pipeline using DeMixT

F. Zhang, S. Cao, Zeya Wang, 2019, bioRxiv.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes

Jeffrey S. Morris, F. Meric-Bernstam, R. Broaddus, 2017, Clinical Cancer Research.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

S. Kopetz, D. Hong, M. Overman, 2019 .

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.

S. Kopetz, R. Wolff, M. Overman, 2022, The oncologist.

Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts

S. Kopetz, M. Overman, A. Sorokin, 2022, Frontiers in Oncology.

Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study

J. Desai, H. Lenz, S. Kopetz, 2018 .

Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic

S. Kopetz, V. Morris, 2022, Nature Reviews Cancer.

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

I. Wistuba, S. Kopetz, A. Futreal, 2022, Journal for ImmunoTherapy of Cancer.

Chromatin Remodeling in Patient-Derived Colorectal Cancer Models

Anders B. Dohlman, G. Crawford, H. Clevers, 2022, bioRxiv.

Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.

O. Margalit, S. Kopetz, Y. Lawrence, 2018, The oncologist.

Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer.

S. Kopetz, M. Overman, E. Vilar, 2019, JCO precision oncology.

Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).

A. Bardelli, R. Yaeger, S. Kopetz, 2021 .

International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel

W. Park, Tae Won Kim, S. Kopetz, 2020 .

1758O Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency

S. Kopetz, M. Overman, E. Vilar, 2021, Annals of Oncology.

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).

L. Diaz, P. Philip, C. Atreya, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Harpreet Wasan, Takayuki Yoshino, Josep Tabernero, 2019, The New England journal of medicine.

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2021 .

SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC

E. Van Cutsem, J. Tabernero, R. Yaeger, 2021, Annals of Oncology.

Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC).

K. Aldape, F. Meric-Bernstam, Ken Chen, 2014 .

Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays

S. Kopetz, Alisha Bent, A. Bent, 2021, Clinical Cancer Research.

Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)

H. Lenz, A. Venook, S. Kopetz, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases.

J. Vauthey, S. Kopetz, M. Overman, 2021, Journal of the American College of Surgeons.

Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement.

A. Grothey, S. Kopetz, B. Clary, 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

M. Sawyer, E. Van Cutsem, H. Lenz, 2019, Journal of Clinical Oncology.

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

J. Desai, H. Lenz, B. Neyns, 2017 .

A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.

S. Kopetz, R. Wolff, M. Overman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.

I. Wistuba, P. Hwu, S. Woodman, 2021, Cancer discovery.

How should BRAF V600E-mutated colorectal cancer be treated?

S. Kopetz, 2018, Clinical advances in hematology & oncology : H&O.

Association of primary (1{degrees}) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor ({alpha}EGFR) therapy.

Jeffrey S. Morris, B. Broom, S. Hamilton, 2016 .

Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.

M. Sawyer, H. Lenz, B. Neyns, 2018 .

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

M. Sawyer, E. Van Cutsem, B. Neyns, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

F. Kaye, S. Kopetz, C. Allegra, 2022, Journal of Hematology & Oncology.

Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).

S. Kopetz, R. Wolff, J. Abbruzzese, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

E. Karunasena, S. Kopetz, R. Wolff, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).

C. Atreya, R. Kurzrock, D. Ryan, 2013 .

Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out

J. Vauthey, B. Nordlinger, S. Kopetz, 2010, Annals of Surgical Oncology.

NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type.

S. Kopetz, M. Overman, J. Willis, 2020 .

Development and Application of Duplex Sequencing Strategy for Cell-Free DNA e Based Longitudinal Monitoring of Stage IV Colorectal Cancer

I. Wistuba, S. Kopetz, R. Luthra, 2022 .

Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis

S. Kopetz, G. Gallick, Michael P. Kim, 2008, Cell and Tissue Research.

Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy.

C. Wood, E. Hawk, S. Kopetz, 2019, Angewandte Chemie.

HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.

F. Meric-Bernstam, Ken Chen, M. Fakih, 2016 .

BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

J. Desai, J. Schellens, J. Tabernero, 2018 .

A path to translation: How 3D patient tumor avatars enable next generation precision oncology.

Kristen M. Naegle, Benjamin J. Raphael, Clifford A. Meyer, 2022, Cancer cell.

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

S. Kopetz, R. Wolff, F. Cabanillas, 2011, Anticancer research.

Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype

A. Maitra, K. Rajapakshe, S. Kopetz, 2022, bioRxiv.

Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer

J. Shen, F. Meric-Bernstam, I. Shureiqi, 2022, JAMA network open.

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors

K. Flaherty, D. Cescon, M. Gerlinger, 2022, JCO precision oncology.

Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.

S. Kopetz, R. Wolff, M. Overman, 2021 .

Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

B. Neyns, S. Kopetz, M. Overman, 2018 .

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis

R. Spizzo, M. Fabbri, G. Calin, 2015, Gut.

Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors

A. Jimeno, S. Kopetz, D. Menter, 2022, Investigational New Drugs.

Targeted exome-based predictors of patterns of progression of colorectal liver metastasis after percutaneous thermal ablation

K. Brock, J. Vauthey, A. Jones, 2022, British Journal of Cancer.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.

Edward J. Kim, H. Lenz, S. Kopetz, 2018 .

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer

F. Meric-Bernstam, S. Kopetz, F. Janku, 2022, JCO precision oncology.

Bioactive lipid metabolism in platelet “first responder” and cancer biology

E. Hawk, A. Sood, S. Kopetz, 2018, Cancer and Metastasis Reviews.

Bioactive lipid metabolism in platelet “first responder” and cancer biology

E. Hawk, A. Sood, S. Kopetz, 2018, Cancer and Metastasis Reviews.

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin

B. Broom, T. LaFramboise, J. Issa, 2016, Oncotarget.

Reply to N. Personeni et al

J. Vauthey, S. Kopetz, A. Andreou, 2011 .

Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC.

E. Holliday, J. Shen, S. Kopetz, 2020 .

Reply to F. Dayyani et al.

S. Kopetz, P. Kasi, A. Aleshin, 2022, JCO precision oncology.

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors

J. Tabernero, S. Kopetz, C. Montagut, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).

R. Kurzrock, D. Ryan, A. Venook, 2012 .

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

K. Hess, F. Meric-Bernstam, R. Kurzrock, 2015, BMC Cancer.

Liquid biopsies for residual disease and recurrence.

N. Rosenfeld, S. Dawson, R. Govindan, 2021, Med.

Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy.

C. Wood, E. Hawk, S. Kopetz, 2019, Angewandte Chemie.

Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer

Matan Hofree, J. Shen, S. Kopetz, 2021, Cancers.

The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men

S. Kopetz, G. Powis, Scott Kopetz, 2012, Clinical Cancer Research.

Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective

Stephanie L. Martch, A. Maitra, J. Shen, 2022, Cancer metastasis reviews.

The Provocative Roles of Platelets in Liver Disease and Cancer

Stephanie L. Martch, J. Shen, A. Sood, 2021, Frontiers in Oncology.

Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection

J. Vauthey, S. Kopetz, M. Overman, 2017, Surgery.

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy

S. Kopetz, M. Overman, A. Sorokin, 2018, Front. Oncol..

Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma

J. Ajani, Steven H. Lin, S. Kopetz, 2017, Oncotarget.

Platelets and cancer: a casual or causal relationship: revisited

A. Sood, S. Kopetz, S. Tucker, 2014, Cancer and Metastasis Reviews.

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Kimberly R. Jordan, S. Kopetz, T. Pitts, 2019, Journal of Immunotherapy for Cancer.

Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer

K. Hess, C. Wood, R. Broaddus, 2016, Cancer.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

M. Sawyer, E. Van Cutsem, H. Lenz, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

J. Desai, H. Lenz, S. Kopetz, 2017, The Lancet. Oncology.

Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic Chemotherapy

E. Abdalla, J. Vauthey, S. Kopetz, 2009, Annals of Surgical Oncology.

SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.

J. Vauthey, S. Kopetz, C. Conrad, 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

S. Kopetz, M. Overman, H. Tran, 2011, Clinical Cancer Research.

How liquid biopsies can change clinical practice in oncology.

A. Bardelli, S. Kopetz, J. Seoane, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer

S. Kopetz, H. Hochster, H. Xiong, 2018, Investigational New Drugs.

5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits

E. Giannoni, S. Kopetz, E. Sacco, 2015, Oncotarget.

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

D. Pe’er, A. Cornish, P. Sharma, 2019, Nature Medicine.

Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?

S. Kopetz, Michael S. Lee, 2021, Journal of the National Cancer Institute.

Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer

F. Meric-Bernstam, Anil Korkut, S. Kopetz, 2021, Clinical Cancer Research.

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

S. Kopetz, Richard J Lee, D. Heimbrook, 2012, Cancer research.

Topoisomerase IIα in Chromosome Instability and Personalized Cancer Therapy

Wei Zhang, Ping Ji, Wei Zhang, 2014, Oncogene.

ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma

Douglas B. Evans, Huamin Wang, S. Kopetz, 2011, PloS one.

Clinical actionability enhanced through deep targeted sequencing of solid tumors.

Yuan Qi, Ken Chen, Zechen Chong, 2015, Clinical chemistry.

Clinical Associations of Treatment Failure After Radiation Therapy for Colorectal Liver Metastases

E. Holliday, C. Taniguchi, J. Vauthey, 2020 .

Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers

Kyle R Jackson, A. Maitra, D. Tuveson, 2020, Nature Communications.

Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS

P. A. Futreal, X. Yi, S. Kopetz, 2019, Modern Pathology.

Recent developments in the treatment of metastatic colorectal cancer

S. Kopetz, J. Loree, 2017, Therapeutic advances in medical oncology.

Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.

S. Kopetz, J. Loree, K. Raghav, 2017, Journal of gastrointestinal oncology.

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

James X. Sun, F. Meric-Bernstam, D. Fabrizio, 2017, JCI insight.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

J. Guinney, J. Tabernero, S. Kopetz, 2017, Nature Reviews Cancer.

Predictive and Prognostic Markers in Colorectal Cancer

S. Kopetz, B. George, 2011, Current oncology reports.

MicroRNAs, ultraconserved genes and colorectal cancers.

G. Calin, S. Rossi, R. Davuluri, 2010, The international journal of biochemistry & cell biology.

Targeted Therapy in Colorectal Cancer

S. Kopetz, 2008 .

Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis

J. Bressler, C. Daniel, S. Kopetz, 2018, Translational oncology.

Platelets, circulating tumor cells, and the circulome

S. Kopetz, D. Menter, Michael Lam, 2017, Cancer and Metastasis Reviews.

ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer

Jeffrey S. Morris, J. Ajani, J. Shen, 2021, Clinical Cancer Research.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer

Amber M. Johnson, Ann M. Bailey, F. Meric-Bernstam, 2018, Journal of the National Cancer Institute.

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

O. W. Lindwasser, J. Zell, M. Diehn, 2020, Nature Reviews Clinical Oncology.

Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer

J. Bressler, C. Daniel, S. Kopetz, 2019, BMC Cancer.

Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

G. Mills, J. Marshall, R. Broaddus, 2021, Clinical Cancer Research.

Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

S. Kopetz, J. Loree, S. Napolitano, 2019, Clinical Cancer Research.

Expanded RAS: refining the patient population.

Chloe E Atreya, C. Atreya, S. Kopetz, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical biomarkers in colorectal cancer.

S. Kopetz, V. Morris, 2013, Clinical advances in hematology & oncology : H&O.

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Michael A. Davies, Gordon B. Mills, John M. Mariadason, 2012, Clinical Cancer Research.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Yvonne A. Evrard, Michael W. Lloyd, Jeffrey H. Chuang, 2021, Nature Genetics.

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.

Ann M. Bailey, Yuan Qi, Y. Qi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

C. N. Coleman, P. Okunieff, B. Freidlin, 2013 .

Platelets and cancer: a casual or causal relationship: revisited

A. Sood, S. Kopetz, S. Tucker, 2014, Cancer and Metastasis Reviews.

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers

Funda Meric-Bernstam, Vijaykumar Holla, Beate Litzenburger, 2019, JCO precision oncology.

Untying the gordion knot of targeting MET in cancer.

Ann M. Bailey, R. Salgia, S. Kopetz, 2018, Cancer treatment reviews.

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.

R. DePinho, Jun Li, Y. A. Wang, 2019, Cancer cell.

Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs

L. Ellis, A. Sood, S. Kopetz, 2014, Molecular Cancer Therapeutics.

Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression

L. Ellis, A. Satelli, S. Kopetz, 2014, Clinical Cancer Research.

DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway

Richard G. Fowler, P. Scheet, M. Tetzlaff, 2018, Clinical Cancer Research.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.

L. Ellis, J. Unger, S. Kopetz, 2019, JAMA oncology.

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma

I. Shureiqi, S. Kopetz, R. Wolff, 2017, Oncotarget.

Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

S. Kopetz, Michael S. Lee, 2015, Clinical colorectal cancer.

BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications

S. Kopetz, V. Morris, W. Qiao, 2015, Current Colorectal Cancer Reports.

Models and Technologies Cancer In Silico Drug Discovery : A Systems Biology Tool for Identifying Candidate Drugs to Target Speci fi c Molecular Tumor Subtypes

P. Scheet, S. Kopetz, E. Vilar, 2014 .

FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Ann M. Bailey, V. Baladandayuthapani, Han Liang, 2014, American journal of physiology. Gastrointestinal and liver physiology.

Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients

Ju-Seog Lee, S. Kopetz, B. Sohn, 2014, Clinical Cancer Research.

Genetic profiling as a clinical tool in advanced parathyroid carcinoma

R. Broaddus, S. Kopetz, S. Sherman, 2019, Journal of Cancer Research and Clinical Oncology.

Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research

S. Kopetz, T. Heffernan, G. Draetta, 2019, Cancers.

Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer

C. Daniel, S. Kopetz, H. Tran, 2015, Cancer.

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer

J. Vauthey, S. Kopetz, M. Overman, 2015, British Journal of Cancer.

Global and targeted serum metabolic profiling of colorectal cancer progression

Xifeng Wu, Y. Ye, D. Chang, 2017, Cancer.

Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility

J. Ajani, G. Calin, S. Kopetz, 2020, Gut.

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance

I. Waizenegger, C. Bristow, S. Kopetz, 2023, bioRxiv.

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma

I. Shureiqi, S. Kopetz, R. Wolff, 2019, British Journal of Cancer.

Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics

R. Broaddus, S. Kopetz, M. Overman, 2018, Clinical colorectal cancer.

PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).

H. Lenz, J. Larson, A. Cercek, 2021 .

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis

R. Spizzo, M. Fabbri, G. Calin, 2015, Gut.

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

J. Grandis, M. Hung, Yueh-Fu Fang, 2015, The Journal of clinical investigation.

Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer

S. Kopetz, B. Johnson, 2020, Targeted Oncology.

Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.

I. Wistuba, C. Behrens, R. Broaddus, 2017, The Journal of molecular diagnostics : JMD.

Survival improvement for patients with metastatic colorectal cancer over twenty years

J. Shen, J. Vauthey, S. Kopetz, 2023, npj Precision Oncology.

Resolving clonal substructure from single cell genomic data using CopyKit

N. Navin, S. Kopetz, M. Edgerton, 2022, bioRxiv.

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

S. Curley, E. Abdalla, J. Vauthey, 2009, JAMA.

N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration

Aristeidis G. Telonis, M. Esteller, R. Spizzo, 2017, Genome Biology.

MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer

R. Kucherlapati, I. Shmulevich, Wei Zhang, 2017, The Journal of pathology.

Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases.

Douglas B. Evans, E. Abdalla, S. Kopetz, 2008, Clinical colorectal cancer.

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

I. Tsigelny, C. Atreya, F. Meric-Bernstam, 2018, Cancer discovery.

RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

Steven A. Curley, Andreas Andreou, Thomas A. Aloia, 2013, Annals of surgery.

Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype

E. Ruppin, A. Maitra, K. Rajapakshe, 2023, bioRxiv.

Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer

J. Lillard, S. Kopetz, C. Young, 2021, Cancers.

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

S. Kopetz, F. Ciardiello, T. Troiani, 2019, Journal of Experimental & Clinical Cancer Research.

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer

Jeffrey S. Morris, G. Calin, J. Vauthey, 2019, British Journal of Cancer.

KRAS-IRF 2 Axis Drives Im mune Suppression and Immune Therapy Resistance in Colorectal Cancer Graphical

R. DePinho, Jun Li, Y. A. Wang, 2019 .

Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.

P. Sharma, J. Blando, J. Allison, 2016 .

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Edward J. Kim, H. Lenz, S. Kopetz, 2022, The oncologist.

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6

L. Kwong, S. Kopetz, A. Sorokin, 2022, Cancer research.

Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer.

J. Bressler, C. Daniel, S. Kopetz, 2020, Clinical colorectal cancer.

Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.

G. Mills, E. Jonasch, G. Peng, 2020, Cancer cell.

Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer

J. Bressler, C. Daniel, S. Kopetz, 2019, BMC Cancer.

Clinical and molecular characterization of early‐onset colorectal cancer

Jeffrey S. Morris, F. Meric-Bernstam, R. Broaddus, 2019, Cancer.

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2

P. Scheet, J. Guinney, E. Hawk, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome

P. Scheet, A. Nicosia, E. Hawk, 2018, JAMA Oncology.

Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

F. Gao, S. Kopetz, A. Goel, 2018, Clinical Cancer Research.

Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer

S. Kopetz, Y. Chun, J. Loree, 2018, Current Treatment Options in Oncology.

Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development

Robert S Chapkin, S. Kopetz, Yu Li, 2017, PLoS pathogens.

The potential role of platelets in the consensus molecular subtypes of colorectal cancer

S. Kopetz, J. Roszik, D. Menter, 2017, Cancer and Metastasis Reviews.

Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases.

K. Ahrar, J. Vauthey, M. Hicks, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer

K. Shaw, F. Meric-Bernstam, I. Shureiqi, 2017, PloS one.

Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.

S. Kopetz, D. Menter, Michael S. Lee, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?

Jeffrey S. Morris, S. Kopetz, 2016, Clinical Cancer Research.

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

P. Gibbs, J. Desai, O. Sieber, 2011, Cancer.

Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.

R. Salazar, I. Simon, J. Tabernero, 2013 .

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Jeffrey S. Morris, L. Ellis, S. Kopetz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

cancer metastatic progression and chromosomal instability in colon , a novel noncoding RNA mapping to 8 q 24 , underlies CCAT 2 Material Supplemental

J. Foekens, A. Sieuwerts, S. Thibodeau, 2013 .

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

J. Desai, L. Saltz, S. Kopetz, 2010 .

P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

J. Tabernero, R. Yaeger, S. Kopetz, 2021, Annals of Oncology.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

C. Nadal, R. Salazar, A. Bardelli, 2018, JAMA oncology.

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.

Amber C. Donahue, J. Desai, Zhou Zhu, 2021 .

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

J. Desai, E. Van Cutsem, J. Tabernero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

M. Fakih, S. Kopetz, E. Chan, 2022, The oncologist.

An analysis of research biopsy core variability from over 5000 prospectively collected core samples

J. Lee, Sanjay Gupta, S. Kopetz, 2021, npj Precision Oncology.

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

K. Hess, R. Broaddus, S. Kopetz, 2020, Scientific Reports.

Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.

Jeffrey S. Morris, F. Meric-Bernstam, Ken Chen, 2019, JCO precision oncology.

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Jesse S. Voss, James X. Sun, A. Grothey, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling

Sung Ho Lee, H. Ji, P. McCrea, 2018, Nature Cell Biology.

Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.

Jeffrey S. Morris, Jeffrey E. Lee, J. Vauthey, 2021, Journal of the American College of Surgeons.

Modeling of Patient-Derived Xenografts in Colorectal Cancer

Jeffrey S. Morris, B. Broom, C. Bristow, 2017, Molecular Cancer Therapeutics.

The Long Noncoding RNA CCAT2 induces chromosomal instability through BOP1 - AURKB signaling.

Lucas C. Reineke, S. Hanash, G. Varani, 2020, Gastroenterology.

Metastasis regulation by PPARD expression in cancer cells.

Jeffrey S. Morris, Jing Wang, A. Rashid, 2017, JCI insight.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

J. Tabernero, A. Grothey, S. Kopetz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome

C. Pilarsky, B. Broom, R. Grützmann, 2013, PloS one.

How liquid biopsies can change clinical practice in oncology.

A. Bardelli, S. Kopetz, J. Seoane, 2019 .

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

F. Meric-Bernstam, Helen J. Huang, I. Shureiqi, 2016, Cancer discovery.

The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.

S. Kopetz, C. Lieu, 2010, Clinical colorectal cancer.

Src Continues Aging: Current and Future Clinical Directions

S. Kopetz, G. Gallick, Scott Kopetz, 2007, Clinical Cancer Research.

Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer

X. Yi, S. Kopetz, P. A. Futreal, 2020, Cell Death & Disease.

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

D. Cescon, M. Gerlinger, J. Sosman, 2022, medRxiv.

BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

S. Kopetz, G. Falchook, M. Cabanillas, 2015, Hormones and Cancer.

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

L. Kwong, S. Kopetz, G. Powis, 2016, Oncotarget.

Overcoming resistance to MAPK pathway inhibitors.

S. Kopetz, M. Davies, 2013, Journal of the National Cancer Institute.

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF(V600E) Mutation

Atkins, Siqing, F. Meric-Bernstam, 2022 .

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature

G. Mills, B. Litzenburger, K. Shaw, 2017, Oncotarget.

BRAF-Directed Therapy in Metastatic Colorectal Cancer.

S. Kopetz, K. Korphaisarn, 2016, Cancer journal.

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

J. Hecht, A. Grothey, S. Kopetz, 2015, Cancer treatment reviews.

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

S. Kopetz, Ying Ma, Vikas Kumar, 2009, Journal of hematology & oncology.

Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.

R. Kurzrock, S. Kopetz, A. Naing, 2012, Clinical colorectal cancer.

Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.

G. Mills, Y. Qi, L. Strong, 2015 .

RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases

J. Shindoh, J. Vauthey, S. Kopetz, 2014, Annals of Surgical Oncology.

Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.

P. Scheet, F. Meric-Bernstam, S. Kopetz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

M. Hung, W. Xia, S. Kopetz, 2017, American journal of cancer research.

Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer

J. Shen, S. Kopetz, R. Wolff, 2021, JCO precision oncology.

Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy

J. Shen, S. Kopetz, T. Troiani, 2022 .

A Bayesian phase I/II platform design for co‐developing drug combination therapies for multiple indications

Jin Xu, Ying Yuan, S. Kopetz, 2021, Statistics in medicine.

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

D. Tu, S. Kopetz, H. Kennecke, 2020, Clinical Cancer Research.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

S. Kopetz, D. Hong, M. Overman, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

R. Murthy, M. Hicks, S. Kopetz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies

K. Shaw, M. Tetzlaff, Jiexin Zhang, 2020, Oncotarget.

First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors

Dejan Juric, Keith T Flaherty, Michael A Davies, 2018, Cancer.

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory

Amber M. Johnson, Nora S. Sanchez, Ann M. Bailey, 2017, Oncotarget.

Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases

O. Lichtarge, J. Vauthey, S. Kopetz, 2017, Annals of surgery.

The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer

S. Hanash, P. Scheet, J. Petrosino, 2019, BMC Cancer.

A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease

S. Kopetz, R. Wolff, M. Overman, 2012, Annals of Surgical Oncology.

Chemotherapy with 5‐fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma

Jeffrey S. Morris, J. Ajani, S. Kopetz, 2008, Cancer.

Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.

V. Moreno, G. Capellá, R. Salazar, 2015, The oncologist.

Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer.

G. Genovese, C. Bristow, S. Seth, 2021, Gastroenterology.

BRAF inhibitors in clinical oncology

S. Kopetz, V. Morris, 2013, F1000prime reports.

Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine

S. Kopetz, R. Wolff, M. Overman, 2010, Acta oncologica.

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma

J. Ajani, Steven H. Lin, S. Kopetz, 2019, Therapeutic advances in medical oncology.

Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know

A. Bardelli, Sanjay Gupta, S. Kopetz, 2020, European Radiology.

Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.

J. Vauthey, C. Charnsangavej, Huamin Wang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases

J. Vauthey, S. Kopetz, C. Conrad, 2016, Annals of Surgical Oncology.

Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy

S. Curley, E. Abdalla, J. Vauthey, 2013, Annals of surgery.

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2020, Journal of Clinical Oncology.

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Tabernero, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases

J. Vauthey, S. Kopetz, C. Conrad, 2018, Annals of Surgical Oncology.

Meta‐analysis of KRAS mutations and survival after resection of colorectal liver metastases

J. Vauthey, S. Kopetz, Liang Li, 2015, The British journal of surgery.

Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies.

L. Ellis, J. Unger, S. Kopetz, 2020, The oncologist.

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

L. Ellis, S. Curley, E. Abdalla, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases

J. Vauthey, S. Kopetz, M. De Bellis, 2019, Clinical Cancer Research.

overcoming resistance to M aPK Pathway inhibitors

S. Kopetz, M. Davies, Scott Koptez, 2012 .

The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells

L. Ellis, F. Fan, S. Kopetz, 2014, British Journal of Cancer.

CliP: subclonal architecture reconstruction of cancer cells in DNA sequencing data using a penalized likelihood model

M. Kimmel, S. Cao, S. Kopetz, 2021, bioRxiv.

Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients

Ju-Seog Lee, S. Kopetz, B. Sohn, 2014, Clinical Cancer Research.

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Jing Wang, J. Roth, F. Meric-Bernstam, 2022, Scientific reports.

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine

S. Kopetz, R. Wolff, M. Overman, 2009, British Journal of Cancer.

Biomarkers in colorectal liver metastases

J. Vauthey, S. Kopetz, S. Yamashita, 2018, The British journal of surgery.

Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases☆

Jeffrey E. Lee, J. Vauthey, S. Kopetz, 2019, Surgery.

Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Jeffrey S. Morris, S. Kopetz, R. Wolff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?

S. Kopetz, R. Bresalier, D. Brenner, 2015, Digestive Diseases and Sciences.

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon

L. Ellis, B. Broom, F. Meric-Bernstam, 2016, Oncotarget.

TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling

Sung Ho Lee, H. Ji, P. McCrea, 2018, Nature Cell Biology.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

A. Jimeno, M. Varella‐Garcia, D. Gao, 2016, International journal of cancer.

Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?

S. Curley, E. Abdalla, J. Vauthey, 2010, Journal of the American College of Surgeons.

Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer

J. Vauthey, S. Kopetz, Xuemei Wang, 2021, Journal of Gastrointestinal Surgery.

Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases

J. Vauthey, S. Kopetz, H. T. Tran Cao, 2020, Journal of Gastrointestinal Surgery.

Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

J. Vauthey, S. Kopetz, Y. Chun, 2019, Journal of the American College of Surgeons.

Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status

K. Ahrar, J. Vauthey, M. Hicks, 2017, The British journal of surgery.

Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases.

Bradford J. Kim, J. Vauthey, S. Kopetz, 2016, Journal of the American College of Surgeons.

RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases

J. Vauthey, S. Kopetz, M. Egger, 2016, Journal of Gastrointestinal Surgery.

Perioperative chemotherapy for resectable hepatic metastases

J. Vauthey, S. Kopetz, 2008, The Lancet.

A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status.

J. Vauthey, S. Kopetz, Xuemei Wang, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Adjuvant chemotherapy for stage II colon cancer.

S. Kopetz, P. Hoff, A. Calabrich, 2008, Oncology.

Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.

A. Grothey, S. Kopetz, A. Dasari, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers.

I. Shureiqi, S. Kopetz, R. Wolff, 2020 .

Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.

A. Karsan, Lucas Swanson, S. Kopetz, 2019, Journal of Clinical Oncology.

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

G. Mills, F. Meric-Bernstam, S. Patel, 2016, Molecular Cancer Therapeutics.

Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.

J. Shindoh, S. Curley, J. Vauthey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases

J. Shindoh, S. Curley, J. Vauthey, 2012, Annals of surgery.

Is resection of colorectal liver metastases after a second‐line chemotherapy regimen justified?

S. Curley, E. Abdalla, J. Vauthey, 2011, Cancer.

methylation and KRAS signaling FXR silencing in human colon cancer by DNA

I. Shureiqi, S. Kopetz, Caimiao Wei, 2016 .

Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways

J. Slopis, R. Kurzrock, S. Kopetz, 2011, Molecular Cancer Therapeutics.

CTCs analysis: an update on technological progress.

S. Kopetz, Shulin Li, D. Menter, 2019, Translational research : the journal of laboratory and clinical medicine.

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

S. Kopetz, Shulin Li, I. Ghobrial, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pulmonary arteriovenous fistula in a patient with renal cell carcinoma

S. Kopetz, S. Tu, C. Jiménez, 2007, European Respiratory Journal.

Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre

J. Gu, C. Daniel, S. Kopetz, 2015, British Journal of Cancer.

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

Jeffrey S. Morris, L. Ellis, E. Lin, 2013, PloS one.

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

Fengqin Gao, S. Kopetz, A. Sorokin, 2022, Cell reports.

Cancer In Silico Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes

P. Scheet, S. Kopetz, F. A. San Lucas, 2014, Molecular Cancer Therapeutics.

77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity

D. Maloney, M. Borad, S. Kopetz, 2022, Regular and Young Investigator Award Abstracts.

Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer.

I. Shureiqi, S. Kopetz, M. Overman, 2019, Clinical colorectal cancer.

Platelet “first responders” in wound response, cancer, and metastasis

E. Hawk, A. Sood, S. Kopetz, 2017, Cancer and Metastasis Reviews.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Catalin C. Barbacioru, C. Barbacioru, M. Fakih, 2019, Clinical Cancer Research.

Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients

A. Satelli, S. Kopetz, Shulin Li, 2016, Scientific Reports.

First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

Jennifer L Moseley, A. Tolcher, S. Kopetz, 2008 .

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.

J. Graham, S. Kopetz, J. Bridgewater, 2022, Journal of Clinical Oncology.

Combined Targeting of STAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer

Huamin Wang, S. Kopetz, J. Freeman, 2014, Clinical Cancer Research.

Cancer Therapy : Preclinical Combined Targeting of STAT 3 / NFk B / COX-2 / EP 4 for Effective Management of Pancreatic Cancer

Huamin Wang, S. Kopetz, J. Freeman, 2014 .

Predictors of health-related quality of life and association with survival may identify colorectal cancer patients at high risk of poor prognosis

Xifeng Wu, Alexander Liang, Y. Ye, 2017, Quality of Life Research.

Examining plasma microRNA markers for colorectal cancer at different stages

Wei Zhang, G. Calin, D. Cogdell, 2016, Oncotarget.

Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer.

H. Kuerer, E. Abdalla, J. Vauthey, 2014, Annals of diagnostic pathology.

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer

M. Ychou, S. Kopetz, M. Overman, 2017, Clinical Cancer Research.

Reply to D.J. Gallagher et al

E. Abdalla, J. Vauthey, S. Kopetz, 2009 .

A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.

J. Issa, S. Kopetz, M. Overman, 2012, Journal of Clinical Oncology.

Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials

S. Kopetz, S. Advani, 2019, Journal of surgical oncology.

From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS

J. Vauthey, S. Kopetz, 2013, Cancer.

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single‐center, open‐label, phase 2 study

Jeffrey S. Morris, Huamin Wang, S. Kopetz, 2017, Cancer.

639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy

Matthew J. Frigault, D. Miklos, D. Maloney, 2022, Regular and Young Investigator Award Abstracts.

LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)

E. Van Cutsem, R. Yaeger, S. Kopetz, 2022, Annals of Oncology.

Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer

J. Skibber, S. Kopetz, B. Feig, 2010, Annals of Surgical Oncology.

Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases

E. Abdalla, J. Vauthey, C. Charnsangavej, 2010, The American journal of surgical pathology.

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo

L. Ellis, F. Fan, S. Kopetz, 2023, PloS one.

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors

I. Wistuba, C. Behrens, R. Broaddus, 2017, Oncotarget.

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors

S. Kopetz, M. Overman, K. Raghav, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of Clinical Oncology.

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).

L. Diaz, C. Atreya, H. Lenz, 2017 .

Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis

A. Karsan, Lucas Swanson, S. Kopetz, 2020, Clinical Cancer Research.

Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.

S. Kopetz, M. Overman, P. Hoff, 2011, Clinical colorectal cancer.

Clinical utility of circulating cell-free DNA in advanced colorectal cancer

Eduardo Vilar, I. Shureiqi, S. Kopetz, 2017, PloS one.

Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.

S. Kopetz, G. Yothers, T. George, 2022, Oncology.

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors

L. Pusztai, A. Grothey, Z. Demko, 2022, JCO precision oncology.

Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).

P. Sharma, J. Blando, J. Allison, 2019, Journal of Clinical Oncology.

Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases

Young Uk Kim, I. Wistuba, J. Vauthey, 2021, Clinical Cancer Research.

Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases.

K. Ahrar, J. Vauthey, Sanjay Gupta, 2018, Journal of vascular and interventional radiology : JVIR.

Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.

A. Khorana, L. Saltz, S. Kopetz, 2020, JCO oncology practice.

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer

A. Grothey, S. Kopetz, M. Malhotra, 2021, BMJ Open.

Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

H. Feilotter, D. Tu, S. Kopetz, 2022, Journal of Clinical Oncology.

484PDAnalysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142

Hao Tang, S. Kopetz, M. Overman, 2017 .

Improving the AJCC/TNM staging classification for colorectal cancer: The prognostic impact of tumor deposits.

E. Holliday, S. Kopetz, P. Das, 2020 .

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay

A. Grothey, S. Kopetz, Z. Wainberg, 2019, JCO precision oncology.

Cytotoxic Chemotherapy for Advanced Colorectal Cancer

S. Kopetz, P. Hoff, Facp., 2005 .

Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.

S. Mortimer, J. Vauthey, S. Kopetz, 2017 .

Development and Application of Duplex Sequencing Strategy for Cell-Free DNA (cfDNA)-Based Longitudinal Monitoring of Stage IV Colorectal Cancer.

I. Wistuba, S. Kopetz, L. Medeiros, 2019, The Journal of molecular diagnostics : JMD.

Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.

S. Kopetz, J. Bendell, M. Middleton, 2018 .

Emerging drugs for colorectal cancer

S. Kopetz, C. Eng, D. Fogelman, 2008 .

Mice and Men The Promise of Patient-Derived Xenografts: The Best Laid Plans of

S. Kopetz, G. Powis, Robert Lemos, 2012 .

PI-3-Kinase inhibitors in colorectal cancer.

S. Kopetz, G. Powis, N. Ihle, 2011, Current cancer drug targets.

Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Manal M. Hassan, K. Shaw, S. Kopetz, 2016, Journal of gastrointestinal oncology.

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.

S. Kopetz, M. Overman, H. Lenz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature

S. Kopetz, Maliha Khan, W. Foo, 2017, Case reports in oncological medicine.

Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status.

F. Giuliante, S. Kopetz, K. Hasegawa, 2021, The British journal of surgery.

Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection

K. Ahrar, J. Vauthey, Sanjay Gupta, 2017, Journal of Gastrointestinal Surgery.

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

K. Hess, F. Meric-Bernstam, R. Kurzrock, 2015, BMC Cancer.

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma

I. Shureiqi, S. Kopetz, R. Wolff, 2017, British Journal of Cancer.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy

K. Hess, P. Bhosale, S. Kopetz, 2018, Journal of immunotherapy.

Clinical findings of a palliative care consultation team at a comprehensive cancer center.

E. Bruera, S. Kopetz, N. Dhillon, 2008, Journal of palliative medicine.

Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence‐free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy

L. Ellis, A. Rashid, J. Skibber, 2013, Cancer.

263 A2B694, an autologous logic-gated cell therapy targeting mesothelin

M. Borad, S. Kopetz, J. Welch, 2022, Regular and Young Investigator Award Abstracts.

A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma.

I. Wistuba, P. Hwu, A. Malpica, 2020 .

Barriers to Integrating Gene Profiling for Stage II Colon Cancer

S. Kopetz, J. Abbruzzese, 2009, Clinical Cancer Research.

First-inhuman trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

James X. Sun, F. Meric-Bernstam, D. Fabrizio, 2018 .

Ras Inhibition and the Survival Benefit Favoring Zoledronic Acid Compared With Denosumab in Patients With Multiple Myeloma

J. Vauthey, S. Kopetz, A. Andreou, 2011 .

P-54 Phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: Cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer

S. Kopetz, A. Naing, H. Mamdani, 2022, Annals of Oncology.

Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness.

S. Kopetz, R. Wolff, M. Overman, 2008, Clinical colorectal cancer.

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

S. Kopetz, D. Hong, T. Yap, 2017, Cancer discovery.

Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma

J. Ajani, Steven H. Lin, M. Tetzlaff, 2019, Oncotarget.

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instabili

N. Wolmark, P. Ganz, S. Kopetz, 2021, Journal of Clinical Oncology.

Platelet microparticles: small payloads with profound effects on tumor growth.

S. Kopetz, D. Menter, Jennifer S. Davis, 2017, Non-coding RNA investigation.

Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy

T. Bekaii-Saab, S. Kopetz, T. Zemla, 2019, Clinical research.

Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.

Amber M. Johnson, Nora S. Sanchez, F. Meric-Bernstam, 2018 .

Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF‐PU.1‐DPP4 Axis

Anders B. Dohlman, Robert C. Mines, G. Crawford, 2021, Advanced science.

Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.

Yuan Qi, G. Mills, Y. Qi, 2019, JCO precision oncology.

The potential role of platelets in the consensus molecular subtypes of colorectal cancer

Jeffrey S. Morris, S. Kopetz, J. Roszik, 2017, Cancer and Metastasis Reviews.

A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer.

S. Kopetz, M. Overman, P. Hoff, 2012, European journal of cancer.

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

E. Van Cutsem, J. Tabernero, R. Yaeger, 2021, ESMO open.

SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

J. Tabernero, R. Yaeger, S. Kopetz, 2020 .

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer

L. Altucci, J. Tabernero, S. Kopetz, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab.

J. Vauthey, S. Kopetz, E. Loyer, 2011, AJR. American journal of roentgenology.

Association between KRAS mutation and lung metastasis in advanced colorectal cancer

J. Vauthey, S. Kopetz, M. Overman, 2014, British Journal of Cancer.

The characteristics of ARID1A mutations in colorectal cancer.

F. Meric-Bernstam, R. Broaddus, S. Kopetz, 2018 .

Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer

J. Shen, J. Vauthey, S. Kopetz, 2022, Cancer research communications.

Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA.

I. Wistuba, S. Kopetz, R. Luthra, 2019, Cancer genetics.

The emergence of targetable pathways in colorectal cancer.

S. Kopetz, I. Yu, 2021, Clinical advances in hematology & oncology : H&O.

The oncogenic role of Streptococcus gallolyticus subsp. gallolyticus is linked to activation of multiple cancer-related signaling pathways

P. Sansonetti, S. Kopetz, P. Poullet, 2023, bioRxiv.

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors

M. Fukushima, M. Thomas, S. Kopetz, 2008, Investigational New Drugs.

Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)?

J. Skibber, S. Kopetz, B. Minsky, 2016 .

Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.

J. Skibber, I. Shureiqi, S. Kopetz, 2014, International journal of radiation oncology, biology, physics.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers

J. Ajani, Ju-Seog Lee, S. Kopetz, 2017, Nature Communications.

Comparison of Prognostic Genomic Predictors in Colorectal Cancer

Ju-Seog Lee, I. Chu, S. Kopetz, 2013, PloS one.

Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.

B. Litzenburger, J. Lee, F. Meric-Bernstam, 2015 .

Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.

F. Meric-Bernstam, I. Shureiqi, S. Kopetz, 2015 .

Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.

C. Atreya, R. Kurzrock, D. Ryan, 2014 .

Systematic survey of therapeutic trials for metastatic colorectal cancer.

S. Kopetz, R. Wolff, M. Overman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.

I. Shureiqi, S. Kopetz, R. Wolff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

P. Philip, S. Kopetz, G. Yothers, 2023, Journal of Clinical Oncology.

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

N. Wolmark, S. Kopetz, G. Yothers, 2020, Journal of Clinical Oncology.

Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases

J. Vauthey, S. Kopetz, C. Conrad, 2016, Annals of surgery.

Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

J. Desai, H. Lenz, B. Neyns, 2017 .

517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

J. Desai, J. Schellens, A. Grothey, 2017 .

Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.

F. Meric-Bernstam, S. Kopetz, F. Janku, 2020 .

Germline Cancer Risk Profiles of Patients With Young-Onset Colorectal Cancer: Findings From a Prospective Universal Germline Testing and Telegenetics Program

J. Skibber, S. Kopetz, E. Vilar, 2022, Diseases of the colon and rectum.

Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer.

S. Kopetz, J. Loree, 2017, The Journal of the National Comprehensive Cancer Network.

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

N. Wolmark, S. Kopetz, G. Yothers, 2020 .

Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.

Minetta C. Liu, B. Somer, S. Kopetz, 2023, Journal of Clinical Oncology.

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

P. Philip, S. Kopetz, G. Yothers, 2022, Journal of Clinical Oncology.

Emerging drugs for colorectal cancer.

S. Kopetz, C. Eng, D. Fogelman, 2008, Expert Opinion on Emerging Drugs.

Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.

R. Yaeger, S. Kopetz, A. Pereira, 2018 .

BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials

P. Thall, S. Kopetz, Fangrong Yan, 2023, Clinical trials.

ARID1A mutation to define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer.

Jeffrey S. Morris, J. Ajani, J. Shen, 2020 .

Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

J. Vauthey, S. Kopetz, A. Jaimovich, 2022, Annals of surgery.

A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting.

U. Şahin, S. Kopetz, J. Maurel, 2022, Journal of Clinical Oncology.

First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).

K. Flaherty, G. Shapiro, D. Juric, 2015 .

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.

L. Ellis, S. Kopetz, M. Overman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer.

J. Shen, H. Lenz, S. Kopetz, 2023, JCO precision oncology.

Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer.

Jeffrey S. Morris, J. Vauthey, S. Kopetz, 2012 .

316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study

E. Van Cutsem, R. Yaeger, S. Kopetz, 2022, Annals of Oncology.

229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer

D. Maloney, M. Borad, T. Welling, 2022, Regular and Young Investigator Award Abstracts.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Steven B. Neuhauser, Yvonne A. Evrard, Michael W. Lloyd, 2019, Nature Genetics.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

Yvonne A. Evrard, David M. Rocke, Jessica J. Andrews, 2022, NAR cancer.

Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival

Jeffrey S. Morris, G. Mills, R. Bernards, 2017, Annals of Surgical Oncology.

Hidden biases in an observational study of bevacizumab beyond progression.

S. Kopetz, J. Abbruzzese, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer.

J. Skibber, S. Kopetz, M. Overman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diverticular disease and cancer risk: More than a gut feeling.

C. Daniel, S. Kopetz, V. Fedirko, 2022, Journal of the National Cancer Institute.

Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.

S. Kopetz, M. Overman, A. Pereira, 2018 .

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Schellens, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.

J. Skibber, S. Kopetz, P. Das, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma

J. Shen, S. Kopetz, Michael White, 2023, medRxiv.

Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.

S. Kopetz, V. Morris, S. Napolitano, 2019, Oncology.

Abstract 35: A universal marker for the detection of epithelial-mesenchymal transitioned circulating tumor cells and their prognostic relevance in epithelial cancers

A. Satelli, S. Kopetz, M. Overman, 2014 .

Decellularized organ biomatrices facilitate quantifiable in vitro 3D cancer metastasis models.

Alex J. Walsh, S. Kopetz, S. Raghavan, 2022, Soft matter.

A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer

S. Kopetz, R. Wolff, J. Abbruzzese, 2008, British Journal of Cancer.

Metastasis of cancer: when and how?

I. Wistuba, S. Kopetz, J. Zhang, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.

S. Kopetz, M. Overman, A. Dasari, 2021 .

S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC).

C. Atreya, H. Lenz, S. Kopetz, 2015 .

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAF-Directed Therapy in Metastatic Colorectal Cancer.

S. Kopetz, K. Korphaisarn, 2016, Cancer journal.

Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy

S. Curley, E. Abdalla, J. Vauthey, 2013, Annals of Surgery.

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

S. Curley, E. Abdalla, J. Vauthey, 2009, JAMA.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

A. Jimeno, D. Gao, S. Kopetz, 2016, International journal of cancer.

Platelets, circulating tumor cells, and the circulome

S. Kopetz, D. Menter, Michael Lam, 2017, Cancer and Metastasis Reviews.

Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer.

S. Kopetz, D. Cunningham, H. Tran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.

J. Shindoh, S. Curley, J. Vauthey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer

S. Kopetz, R. Wolff, J. Abbruzzese, 2007 .

Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.

J. Skibber, I. Shureiqi, S. Kopetz, 2014, International journal of radiation oncology, biology, physics.

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.

A. Sood, S. Kopetz, S. Piha-Paul, 2023, The oncologist.

Biomarker-guided therapy for colorectal cancer: strength in complexity

R. Lothe, S. Kopetz, A. Sveen, 2019, Nature Reviews Clinical Oncology.

Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.

F. Meric-Bernstam, R. Broaddus, A. Grothey, 2018 .

Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC).

S. Kopetz, R. Wolff, F. Janku, 2018 .

Chemotherapy with 5‐fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma

Jeffrey S. Morris, J. Ajani, S. Kopetz, 2008, Cancer.

Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer

X. Yi, S. Kopetz, Yuhua Gong, 2020, Cell Death & Disease.

Challenges and strategies for identifying biomarkers for colorectal cancer.

S. Kopetz, Bruno Conte, 2013, Colorectal cancer.

Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.

R. Kurzrock, S. Kopetz, A. Naing, 2012, Clinical colorectal cancer.

New therapies and insights into the changing landscape of colorectal cancer

S. Kopetz, 2018, Nature Reviews Gastroenterology & Hepatology.

Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies

G. Pillonetto, S. Kopetz, A. Yazdani, 2024, Research square.

Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).

I. Wistuba, S. Kopetz, F. Janku, 2018 .

Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

S. Kopetz, M. Overman, K. Raghav, 2023, Cancer research communications.

Chromatin Remodeling in Patient‐Derived Colorectal Cancer Models

Anders B. Dohlman, G. Crawford, H. Clevers, 2022, bioRxiv.

Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer.

S. Kopetz, V. Morris, A. Dasari, 2019, Journal of Clinical Oncology.